# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2014 Earnings Results

**Report date:** 2014-11-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2014

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 5.79%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.52 | N/A | +20.00% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in the company's future growth. They emphasized the importance of their product pipeline and ongoing R&D efforts.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They noted ongoing investments in research and development.

> There was an emphasis on maintaining a robust pipeline.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 5.79% on the day, likely due to the lack of revenue details and forward guidance. Investors may be concerned about future performance without clearer expectations from management.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2014_